{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:39:04Z","timestamp":1773257944020,"version":"3.50.1"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent work has identified L1CAM (CD171) as a novel marker for human carcinoma progression. Functionally, L1CAM promotes tumor cell invasion and motility, augments tumor growth in nude mice, and facilitates experimental tumor metastasis. These functional features qualify L1 as an interesting target molecule for tumor therapy. Here, we generated a series of novel monoclonal antibodies (mAb) to the L1CAM ectodomain that were characterized by biochemical and functional means. All novel mAbs reacted specifically with L1CAM and not with the closely related molecule CHL1, whereas antibodies to the COOH terminal part of L1CAM (mAb2C2, mAb745H7, pcytL1) showed cross-reactivity. Among the novel mAbs, L1-9.3 was selected and its therapeutic potential was analyzed in various isotype variants in a model of SKOV3ip cells growing i.p. in CD1 nude mice. Only therapy with the IgG2a variant efficiently prolonged survival and reduced tumor burden. This was accompanied by an increased infiltration of F4\/80-positive monocytic cells. Clodronate pretreatment of tumor-bearing animals led to the depletion of monocytes and abolished the therapeutic effect of L1-9.3\/IgG2a. Expression profiling of tumor-derived mRNA revealed that L1-9.3\/IgG2a therapy induced altered expression of cellular genes associated with apoptosis and tumor growth. Our results establish that anti-L1 mAb therapy acts via immunologic and nonimmunologic effector mechanism to block tumor growth. The novel antibodies to L1CAM could become helpful tools for the therapy of L1-positive human carcinomas. Cancer Res; 70(6); 2504\u201315<\/jats:p>","DOI":"10.1158\/0008-5472.can-09-3730","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T22:17:28Z","timestamp":1268173048000},"page":"2504-2515","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma"],"prefix":"10.1158","volume":"70","author":[{"given":"Silke","family":"Wolterink","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Gerhard","family":"Moldenhauer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Mina","family":"Fogel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Helena","family":"Kiefel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Marco","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Sandra","family":"L\u00fcttgau","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Ricardo","family":"Gouveia","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Julia","family":"Costa","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Jan","family":"Endell","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Ulrich","family":"Moebius","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]},{"given":"Peter","family":"Altevogt","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Tumor Immunology Program, Translational Immunology Unit (D015), German Cancer Research Center, Heidelberg, Germany; 2Department for Pathology, Kaplan Medical Center, Rehovot, Israel; 3Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Oeiras, Portugal; and 4Medigene AG, Martinsried, Germany"}]}],"member":"1086","published-online":{"date-parts":[[2010,3,14]]},"reference":[{"key":"2022061702551987300_bib1","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1200\/JCO.2007.15.7438","article-title":"Monoclonal antibodies in cancer therapy: 25 years of progress","volume":"26","author":"Oldham","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061702551987300_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2022061702551987300_bib3","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nbt0905-1073","article-title":"Monoclonal antibody successes in the clinic","volume":"23","author":"Reichert","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2022061702551987300_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1359-6446(03)02714-4","article-title":"Renaissance of cancer therapeutic antibodies","volume":"8","author":"Glennie","year":"2003","journal-title":"Drug Discov Today"},{"key":"2022061702551987300_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2022061702551987300_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061702551987300_bib7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2022061702551987300_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0140-6736(06)67951-8","article-title":"Trastuzumab for early breast cancer","volume":"367","author":"Smith","year":"2006","journal-title":"Lancet"},{"key":"2022061702551987300_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061702551987300_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1634\/theoncologist.2008-0254","article-title":"FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer","volume":"14","author":"Giusti","year":"2009","journal-title":"Oncologist"},{"key":"2022061702551987300_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2022061702551987300_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.coi.2007.01.005","article-title":"Antibodies, Fc receptors and cancer","volume":"19","author":"Nimmerjahn","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"2022061702551987300_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","article-title":"Fc\u03b3 receptors: old friends and new family members","volume":"24","author":"Nimmerjahn","year":"2006","journal-title":"Immunity"},{"key":"2022061702551987300_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0955-0674(97)80115-9","article-title":"Neural recognition molecules and synaptic plasticity","volume":"9","author":"Schachner","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"2022061702551987300_bib15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14712598.8.11.1749","article-title":"L1-CAM in cancerous tissues","volume":"8","author":"Gavert","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"2022061702551987300_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1535-6108(03)00169-7","article-title":"Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements","volume":"4","author":"Primiano","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061702551987300_bib17","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1158\/0008-5472.CAN-08-1079","article-title":"Targeting cancer stem cells through L1CAM suppresses glioma growth","volume":"68","author":"Bao","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702551987300_bib18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/0008-5472.CAN-05-1818","article-title":"Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment","volume":"66","author":"Arlt","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702551987300_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-06-1486","article-title":"Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis","volume":"13","author":"Knogler","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061702551987300_bib20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.onc.1210747","article-title":"The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies","volume":"27","author":"Gast","year":"2008","journal-title":"Oncogene"},{"key":"2022061702551987300_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"2022061702551987300_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1083\/jcb.200101099","article-title":"Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins","volume":"155","author":"Mechtersheimer","year":"2001","journal-title":"J Cell Biol"},{"key":"2022061702551987300_bib23","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1158\/1078-0432.CCR-04-1688","article-title":"Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells","volume":"11","author":"Gutwein","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2022061702551987300_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(94)90012-4","article-title":"Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications","volume":"174","author":"Van Rooijen","year":"1994","journal-title":"J Immunol Methods"},{"key":"2022061702551987300_bib25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(03)14342-5","article-title":"L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas","volume":"362","author":"Fogel","year":"2003","journal-title":"Lancet"},{"key":"2022061702551987300_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0304-3835(02)00513-X","article-title":"L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma","volume":"189","author":"Fogel","year":"2003","journal-title":"Cancer Lett"},{"key":"2022061702551987300_bib27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/intimm\/6.7.1027","article-title":"Heat-stable antigen (CD24) as ligand for mouse P-selectin","volume":"6","author":"Sammar","year":"1994","journal-title":"Int Immunol"},{"key":"2022061702551987300_bib28","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1074\/jbc.275.20.15490","article-title":"Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells","volume":"275","author":"Gutwein","year":"2000","journal-title":"J Biol Chem"},{"key":"2022061702551987300_bib29","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.humpath.2006.03.014","article-title":"Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy","volume":"37","author":"Huszar","year":"2006","journal-title":"Hum Pathol"},{"key":"2022061702551987300_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pep.2006.10.008","article-title":"Production and purification of functional truncated soluble forms of human recombinant L1 cell adhesion glycoprotein from Spodoptera frugiperda Sf9 cells","volume":"52","author":"Gouveia","year":"2007","journal-title":"Protein Expr Purif"},{"key":"2022061702551987300_bib31","doi-asserted-by":"crossref","first-page":"11943","DOI":"10.1016\/S0021-9258(18)37877-3","article-title":"A human brain glycoprotein related to the mouse cell adhesion molecule L1","volume":"263","author":"Wolff","year":"1988","journal-title":"J Biol Chem"},{"key":"2022061702551987300_bib32","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/1521-4141(200003)30:3<938::AID-IMMU938>3.0.CO;2-Q","article-title":"The human neural cell adhesion molecule L1 functions as a costimulatory molecule in T cell activation","volume":"30","author":"Balaian","year":"2000","journal-title":"Eur J Immunol"},{"key":"2022061702551987300_bib33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1083\/jcb.200203024","article-title":"L1 endocytosis is controlled by a phosphorylation-dephosphorylation cycle stimulated by outside-in signaling by L1","volume":"157","author":"Schaefer","year":"2002","journal-title":"J Cell Biol"},{"key":"2022061702551987300_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/IGC.0b013e3181a3cd38","article-title":"Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer","volume":"19","author":"Manderson","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"2022061702551987300_bib35","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/0008-5472.CAN-07-2897","article-title":"The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium","volume":"68","author":"Zecchini","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702551987300_bib36","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin g subclass activity through selective Fc receptor binding","volume":"310","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"2022061702551987300_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bjc.6604812","article-title":"Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40","volume":"100","author":"Oflazoglu","year":"2009","journal-title":"Br J Cancer"},{"key":"2022061702551987300_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ijc.21880","article-title":"The adhesion molecule L1 (CD171) promotes melanoma progression","volume":"119","author":"Meier","year":"2006","journal-title":"Int J Cancer"},{"key":"2022061702551987300_bib39","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4161\/cc.8.5.7887","article-title":"REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells","volume":"8","author":"Chang","year":"2009","journal-title":"Cell Cycle"},{"key":"2022061702551987300_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/0008-5472.CAN-08-3633","article-title":"Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth","volume":"69","author":"Takayama","year":"2009","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/6\/2504\/2648857\/2504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/70\/6\/2504\/2648857\/2504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:33:41Z","timestamp":1655451221000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/70\/6\/2504\/566470\/Therapeutic-Antibodies-to-Human-L1CAM-Functional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,14]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,3,14]]},"published-print":{"date-parts":[[2010,3,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-09-3730","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22386360","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386363.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6501501","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386363","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6501501.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386357.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386357","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386369","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386360.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386366.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386354","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386366","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386369.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22386354.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,14]]}}}